Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RNAZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.14 - $776.65
Previous CloseN/A
Volume52.57K
Average Volume (3M)26.09K
Market Cap
$8.29M
Enterprise Value-$11.56B
Total Cash (Recent Filing)$11.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.21
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.61
Shares Outstanding833,683
10 Day Avg. Volume26,309
30 Day Avg. Volume26,095
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.40K
Enterprise Value/Revenue-7.68K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda158.80
Forecast
1Y Price Target
$10.00Price Target Upside0.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
TransCode Therapeutics News
PremiumCompany Announcements
TransCode Therapeutics Announces 2025 Annual Meeting Date
PremiumCompany Announcements
TransCode Therapeutics Faces Nasdaq Delisting Risk
PremiumCompany Announcements
TransCode Therapeutics Announces Reverse Stock Split
PremiumCompany Announcements
TransCode Therapeutics Announces Reverse Stock Split Approval
Bulls Say, Bears Say
Bulls Say
Clinical EffectivenessThe company observed a miRNA-10b inhibition of ~66% in Cohort 1, indicating the drug's effectiveness even at low doses in the blood.
Clinical Trial ProgressThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Clinical RisksRisks include, but are not limited to: safety signals emerge with any of the company’s clinical or preclinical programs; efficacy from clinical programs is lower than expected or the company’s studies do not achieve statistical significance.
Financial PerformanceIn 4Q24, the company reported operating expenses of $5.1M, which was significantly higher than 3Q24, likely associated with costs related to dose escalation in the Phase 1 trial of TTX-MC138 for treatment of solid tumors.
Options Prices
Currently, No data available
---
Ownership Overview
6.76%
Insiders
0.56% Mutual Funds
― Other Institutional Investors
99.40% Public Companies and
Individual Investors
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $6.14 and its highest was $776.65 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $8.29M.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is 116 days ago.
How were TransCode Therapeutics’s earnings last quarter?
Currently, no data Available
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 833,683 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
TransCode Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (0.60% Upside)
$10.00 (0.60% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.76%
12-Months-Change
Fundamentals
Return on Equity
-342.99%
Trailing 12-Months
Asset Growth
80.98%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics (RNAZ) is a biotechnology company focused on developing RNA-based therapeutics for the treatment of cancer and other diseases. Operating within the pharmaceutical and biotechnology sectors, TransCode leverages its proprietary platform to design and deliver RNA-targeted therapies, aiming to address significant unmet medical needs. The company's core products include a pipeline of therapeutics targeting various forms of cancer, utilizing their expertise in RNA technologies to innovate in precision medicine.